Site Map

Home

Influenza FAQs
     What is seasonal flu?
     How is seasonal flu different from pandemic flu?
     What is avian flu?
     Will avian flu become a pandemic flu?

Pandemic Flu FAQs
     How do pandemic flu viruses develop?
     How would a pandemic flu affect normal, everyday life?
     Who is most at risk during a pandemic flu?
     What are the expected levels of illness and mortality from a pandemic flu?
     What will be the US economic impact of a pandemic flu?
     When will the next pandemic occur?
     What treatments are available for pandemic flu?

Pandemic Flu Preparation
     US government preparations
     Your organization’s preparedness
     Medical and community interventions

Planning Tools & Resources
     Risk Management Calculator
     Resources & Reports
     CDC Planning Checklists
     Information on RELENZA
     More information

Pandemic Flu Video Series
     Introduction
     Assessing Company Needs in Preparation for a Pandemic
     Principles of a Pandemic Plan
     Designing and Delivering a Plan
     Ensuring a Plan is Effective and in Place
     Sample Planning Tools

About RELENZA
     RELENZA and Pandemic Flu
     RELENZA Resistance Profile
     How to Use RELENZA Step-by-Step
     Parts of the DISKHALER
     RELENZA Indications and Important Safety Information

Ordering RELENZA
     RELENZA Stockpiling FAQs
     How to Order RELENZA
          Employee Coverage
          Calculate Number to Order
          Placing An Order
                Distributers
                Wholesalers
          Storage
                Storage Partners
          Distribution
          Education

Contact Information

 
Important Safety Information About RELENZA

• Serious cases of bronchospasm, including fatalities, have been reported during treatment with RELENZA in patients with and without underlying airway disease. Many of these cases were reported during postmarketing, and causality was difficult to assess
  
• RELENZA SHOULD BE DISCONTINUED IN ANY PATIENT WHO DEVELOPS BRONCHOSPASM OR DECLINE IN RESPIRATORY FUNCTION; immediate treatment and hospitalization may be required
  
• Safety and efficacy have not been demonstrated in patients with high-risk underlying medical conditions
  
• Patients should be instructed in the use of the delivery system. Instructions should include a demonstration whenever possible
  
• If treatment with RELENZA is considered for a patient with underlying airway disease, the potential risks and benefits should be carefully weighed. If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care including availability of fast-acting bronchodilators
  
• Common adverse events in treatment and prophylaxis studies with RELENZA were nausea, diarrhea, sinusitis, viral respiratory infections, headaches, nasal signs and symptoms. The incidence of these adverse events was similar in both groups for RELENZA and placebo-treated groups
  
• Please see complete Prescribing Information for RELENZA